Medical device industry titan Boston Scientific lands approval to launch its next-generation Reliance 4-Front defibrillator leads in Europe and Asia.

Medtech titan Boston Scientific (NYSE:BSX) won regulatory approval to market its next-generation Reliance 4-Front defibrillator leads in Europe and Asia, the company announced today.

That may be good news for Boston Scientific's struggling cardiac rhythm management business, which experienced a 10% drop in sales during the company's 1st quarter.

The 4-Front device, which is not yet cleared by the FDA, features novel coatings designed to enhance the device's electrical properties and prevent tissue in-growth into defibrillation coils, according to a press release.